- Home
- COO vs BBIO Comparison
COO vs BBIO Comparison
Compare COO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COO | BBIO |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 14.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | COO | BBIO |
|---|---|---|
| Price | $84.34 | $72.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $88.55 | $77.55 |
| AVG Volume (30 Days) | ★ 2.9M | 1.8M |
| Earning Date | 12-04-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $4,092,400,000.00 | $353,780,000.00 |
| Revenue This Year | $6.56 | $127.64 |
| Revenue Next Year | $5.32 | $78.38 |
| P/E Ratio | $44.25 | ★ N/A |
| Revenue Growth | 5.06 | ★ 62.46 |
| 52 Week Low | $61.78 | $27.86 |
| 52 Week High | $100.24 | $78.59 |
Technical Indicators
Market Signals| Indicator | COO | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 66.90 | 51.57 |
| Support Level | $80.23 | $74.47 |
| Resistance Level | $83.64 | $78.59 |
| Average True Range (ATR) | 1.40 | 2.47 |
| MACD | -0.23 | -0.57 |
| Stochastic Oscillator | 97.88 | 38.27 |
Price Performance
Historical ComparisonAbout COO The Cooper Companies Inc.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.